Wiki for hem channel

HEM.V - Hemostemix Inc.

Image result for Hemostemix logo

HEMOSTEMIX

Welcome to the wiki page for Hemostemix Inc.
created by @BearTank
In collaboration with Thomas Smeenk CEO and Founder of Hemostemix
Subscribe to our channels if you found this informative, show some love!!

Last
week Bristol Myers Squibb paid $13.1 Billion for Myokardia (MYOK) to
obtain Mavacamtem.

Whereas
the comparison of Hemostemix to Myokardia cannot be direct, since
Mavacamtem is a traditional orally-administered small molecule (pill)
that will be paid for by insurance plans and ACP is one-time
autologous stem cell treatment completed in a cath lab, the
comparison of cardiomyopathy patients who were treated with ACP-01
and Mavacamtem can be head-to-head.

Below
are the phase II results of ACP-01 as compared to Mavacamtem's phase
III results in patients suffering from cardiomyopathy. Attached
is a summary of the company's significant data of >300 patients
treated for cardiomyopathy who were followed for up to 3 years.

Whereas
Mavacamtem is a treatment for 1 in 500, ACP is a treatment for a
greater number of patients who suffer from cardiomyopathy, angina,
peripheral arterial disease, and its degenerative condition
critical limb ischemia.

Linked(1
)is the company's investor presentation and quick
overview (2).

ACP
was also used as a compassionate treatment for idiopathic pulmonary
hypertension (3.5
minute video)
(3) with significant results. At the age of 9, Cal was given five
years to live and faced a heart lung transplant. Today, aged 19, Cal
has lived 8 of the last 10 years medication free because of ACP.

Publications
enabling the comparison of ACP to Mavacamtem:

Published
in Asian
Cardiovascular and Thoracic Annals (4) ACP
trialed in Cardiomyopathy has >2X the uptake - 80% - as compared
to Mavacamtem - 37% - (Phase 3 Lancet)
(5)

34%
more patients in the Mavacamten group improved by at least one NYHA
class (80 of 123 patients in the Mavacamten group vs 40
of 128 patients in the placebo group; 95% CI 22·2 to 45·4;
p<0·0001). At
a mean of 180 days after the ACP injection, NYHA functional class
improved one whole class, from 2.69 ± 0.79 preoperatively to 1.63 ±
0.81 in the Dilated Cardiomyopathy group (*n *=
16, *p *<
0.05), and from 3.0 ±0.52 to 1.94 ±0.85 in the Ischemic
Cardiomyopathy group (n =
16, p <
0.05).

The ACP
6-min walk tests showed an improvement of nearly 126 meters in
walking capacity (from 343.3 to 469.4 meters, n =
9, at 90 days).

The
overall ejection fraction (EF) in the ACP groups improved by 4.8
percentage points ± 7.5 percentage points (from 26.2% ± 7.2%
to 31.1% ± 9.0%) at 149 ± 98 days postoperatively (n =
29, p <
0.05). Ejection fraction improved by 2.8 ± 9.1 percentage points
(from 25.9% ± 8.6% to 28.7% ± 9.8%) at 135 ± 88 days in the DCM
group (n =
15, p =
0.3), and 7.1 ± 4.6 percentage points (from 26.6% ± 5.8% to 33.6%
± 7.7 %) at 164 ± 109 days in the ICM group (n =
14, p <
0.05).

ACP
has been trialed in angina successfully (Circulation)(6),
with the following outcomes: The
clinical condition improved in all patients at 3 and 6 months vs.
pretreatment, 6 Minute Walk increased from 333.65 ±26.56 to 414.95
±28.54 meters at 3 months and to 413.25 ±33.17 meters at 6 months
(both P<0.001); exercise capacity increased from 5.62 ±0.52 to
6.73 ±0.64 METs at 3 months (P<0.004) and to 7.09 ±0.79 METs at
6 months (P<0.04); perfusion defect decreased from 38.46 ±6.19%
to 23.89 ±5.79% at 3 months (P<0.004) and to 21.05 ±5.16% at 6
months (P<0.005); and mean CCS score decreased from 2.1 ±0.19 to
1.05 ±0.05 at 3 months and to 1.18 ±0.13 at 6 months (both
P<0.001).

ACP
has been trialed successfully in PAD (Cytotherapy)(7): In
the treated arm after two years: no deaths, 7 of 10 saved their limb
from amputation; in the placebo arm: 2 deaths and 6 limbs lost to
amputation.

ACP
is currently the subject of a double blinded placebo controlled
trial in patients suffering from CLI. Interim data was presented to
the 41st Annual Canadian Society for Vascular Surgery Meeting
on September 14, 2019 by two lead investigators, Dr. York Hsiang,
UBC, and Dr. Thomas Lindsay, U of T. The poster (8)
detailed: "Healing of ulcers and resolution of ischemic rest
pain occurred in 83% of patients...with outcomes maintained for
up to 4.5 years."

Footnotes:
our web addresses of links, in the order cited

Investor
Presentation https://hemostemix.com/wp-content/uploads/2020/06/Corporate-Presentation-June-2020-FINAL.pdf

Overview https://hemostemix.com/wp-content/uploads/2020/06/Hemo3pagerJune2020FINAL.pdf

Cal,
Idiopathic Pulmonary
Hypertension https://www.youtube.com/watch?v=igy6Pt__5uM&t=18s

Intramyocardial
Angiogenic Cell Precursor Injection for Cardiomyopathy, Asian
Cardiovascular & Thoracic
Annals https://hemostemix.com/wp-content/uploads/2020/03/Arom-Asian-Journal-Stem-Cell.pdf

Mavacamten
for treatment of symptomatic obstructive hypertrophic cardiomyopathy
(EXPLORER-HCM): a randomised, double-blind, placebo-controlled,
phase 3
trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31792-X/fulltext

Abstract
3682: Treatment of Patients with Severe Angina Pectoris Using
Intracoronarily Injected Autologous Blood-Borne Angiogenic Cell
Precursors https://www.ahajournals.org/doi/10.1161/circ.114.suppl_18.II_786-c

Peripheral
blood-derived autologous stem cell therapy for the treatment of
patients with late-stage peripheral artery disease-results of the
short- and long-term
follow-up https://pubmed.ncbi.nlm.nih.gov/23993298/

AUTOLOGOUS
STEM CELL TREATMENT FOR CLI PATIENTS WITH NO REVASCULARIZATION
OPTIONS: AN UPDATE OF THE HEMOSTEMIX ACP-01 TRIAL WITH 4.5 YEAR
FOLLOWUP https://hemostemix.com/wp-content/uploads/2019/10/Hemostemix-Poster.pdf

Here is a video link about Hemostemix
https://www.youtube.com/watch?v=9IszVA_cf90

Patient testimonials
https://hemostemix.com/acp-testimonials/

Interview with Thomas Smeenk Dec 9 2020
https://jwp.io/s/rvOeAY3s

A great article about one of the founders Roger Bergerson posted on Stockhouse
https://stockhouse.com/opinion/independent-reports/2020/12/15/hemostemix-founder-a-man-with-compassionate-heart
https://hemostemix.com/2020/03/16/hemostemix-announces-the-passing-of-its-principal-founder-roger-bergersen/

Hemostemix was able to raise $4 million in financings in a very short period of time, Almost 1 third of their market cap at the time
https://ceo.ca/@newsfile/hemostemix-announces-closing-of-existing-private-placement
https://ceo.ca/@newsfile/hemostemix-announces-closing-of-unit-private-placement

A link to the NIH - U.S. National Library of Medicine showing the Phase 2 Trial measures and criteria
https://clinicaltrials.gov/ct2/show/NCT02551679

January 5th 2021 Investor Intel article
https://investorintel.com/markets/biotech-healthcare/biotech-intel/hemostemix-steps-into-the-new-year-with-capital-and-its-critical-clinical-study-data-in-hand/

January 12th 2021 Interview with Peter Clausi (InvestorIntel)
https://www.youtube.com/watch?v=xAMC74YUxlU

January 28th 2021 News release
https://www.newsfilecorp.com/release/73066

February 11th 2021 News Release
https://www.newsfilecorp.com/release/74227

February 11th 2021 Video by Thomas Smeenk
https://stockhouse.com/opinion/interviews/2021/02/11/shaping-future-regenerative-medicine-today

March 18th 2021 News Release
https://www.newsfilecorp.com/redirect/JqwZsEZN5